Chemotherapy: Preventing competitive release.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.Apoptosis : an international journal on programmed cell death · 2022
   Pooled it
2. Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control.Cancer research · 2025
   Article
3. Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
   Article
4. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.Cancer cell international · 2023
   Article
5. Zinc Finger Protein 90 Knockdown Promotes Cisplatin Sensitivity via Nrf2/HO-1 Pathway in Ovarian Cancer Cell.Cancers · 2023
   Article
6. Tumour Genetic Heterogeneity in Relation to Oral Squamous Cell Carcinoma and Anti-Cancer Treatment.International journal of environmental research and public health · 2023
   Review
7. Computational Indicator Approach for Assessment of Nanotoxicity of Two-Dimensional Nanomaterials.Nanomaterials (Basel, Switzerland) · 2022
   Article
8. Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.Aging · 2021
   Article
9. miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2.Biological research · 2020
   Article
10. Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines.Cancers · 2020
    Review
11. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.Cancer research · 2019
    Article
12. Nonlinear adaptive control of competitive release and chemotherapeutic resistance.Physical review. E · 2019
    Article
13. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.Journal of theoretical biology · 2018
    Article
14. MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.Frontiers in oncology · 2018
    Review
15. The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.Oncotarget · 2017
    Article
16. Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance.Toxicological research · 2017
    Review

Corrections and comments

• Comment on
  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.